A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
Active, not recruiting
Eli Lilly and Company
The purpose of this study is to determine a safe dose of LY2835219 to be given to
participants with advanced cancer and to determine any side effects that may be associated
with LY2835219 in this population. Efficacy measures will be used to assess the activity of
LY2835219 in this population.
This type of study is called a radiolabeled study. For this study, LY2835219 (study drug)
has been specially prepared to contain radiolabeled carbon [14C]. [14C] is a naturally
occurring radioactive form of the element carbon. This study will help understand how the
drug appears in the blood, urine, and stool after it is administered.
In addition, this study will also evaluate the safety and tolerability of a single dose of
LY2835219 when given to healthy participants. Information about any side effects that may
occur will also be collected.
This study will last about 3 weeks for each participant, not including screening.
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Eli Lilly and Company
The main purpose of this study is to evaluate the safety of a study drug known as LY2835219
in combination with different therapies (letrozole, anastrozole, tamoxifen, exemestane,
exemestane plus everolimus, trastuzumab, or LY3023414 plus fulvestrant) for breast cancer
that has spread to other parts of the body.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.